Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/17/2899739/0/en/Immix-Biopharma-to-Present-at-the-Stifel-2024-Cell-Therapy-Forum.html
https://www.globenewswire.com/news-release/2024/05/10/2879674/0/en/Immix-Biopharma-Announces-Positive-NXC-201-Relapsed-Refractory-AL-Amyloidosis-Clinical-Data-in-ASGCT-2024-Late-Breaking-Oral-Presentation.html
https://www.globenewswire.com/news-release/2024/04/29/2871345/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-Multiple-Myeloma.html
https://www.globenewswire.com/news-release/2024/04/18/2865508/0/en/Immix-Biopharma-on-Track-to-Dose-NXC-201-Patients-in-United-States.html
https://www.globenewswire.com/news-release/2024/04/15/2862875/0/en/Immix-Biopharma-Announces-Late-Breaking-NXC-201-Clinical-Data-Abstract-Accepted-for-Oral-Presentation-at-the-27th-Annual-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-AS.html
https://www.globenewswire.com/news-release/2024/03/20/2849459/0/en/Immix-Biopharma-Announces-Major-Comprehensive-Cancer-Center-as-Lead-Site-for-NXC-201-AL-Amyloidosis-Clinical-Trial.html
https://www.globenewswire.com//news-release/2024/03/05/2840587/0/en/Immix-Biopharma-Announces-Be-Proactive-in-AL-AL-Amyloidosis-Awareness-Initiative.html
https://www.globenewswire.com//news-release/2024/02/21/2832855/0/en/Immix-Biopharma-12-Month-Review-Progress-Update.html
https://www.globenewswire.com//news-release/2024/02/08/2826486/0/en/Immix-Biopharma-Announces-Closing-of-15-Million-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/02/07/2825304/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-AL-Amyloidosis.html